Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 11/20 | 0.36 |
| ▸ | DHODH | Q02127 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | F2R | P25116 | 3/20 | 0.33 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25085588 | 0.94 | RXFP1 (0.36) | RXFP1DHODHSMN1; SMN2F2RP2RX1 | |
| SCHEMBL23059687 | 0.94 | DHODH (0.37) | RXFP1DHODHSMN1; SMN2F2RP2RX1 | |
| SCHEMBL25085595 | 0.94 | SMN1; SMN2 (0.38) | RXFP1DHODHSMN1; SMN2 | |
| SCHEMBL25085575 | 0.93 | DHODH (0.36) | RXFP1DHODHSMN1; SMN2F2RP2RX1 | |
| SCHEMBL23059688 | 0.90 | DHODH (0.39) | RXFP1DHODHSMN1; SMN2F2R | |
| SCHEMBL23059704 | 0.88 | SMN1; SMN2 (0.36) | RXFP1DHODHSMN1; SMN2F2R | |
| SCHEMBL25085498 | 0.88 | SMN1; SMN2 (0.36) | RXFP1DHODHSMN1; SMN2F2R | |
| SCHEMBL1843056 | 0.86 | ALDH1A1 (0.41) | RXFP1SMN1; SMN2F2RP2RX1P2RX7 | |
| SCHEMBL12658592 | 0.85 | RXFP1 (0.36) | RXFP1SMN1; SMN2F2RP2RX1P2RX7 | |
| SCHEMBL1844085 | 0.85 | RXFP1 (0.36) | RXFP1SMN1; SMN2F2RP2RX1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065544-A1 | ISOPHTHALAMINDE COMPOUND AND USE THEREOF | Metisa Biotechnology Co., Ltd (CN) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065544-A1 | ISOPHTHALAMINDE COMPOUND AND USE THEREOF | DDT, INMT, CYP2B6 | RXFP1 4724/4885DHODH 11/4885SMN1; SMN2 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.